DEA temporarily extends COVID-19 telehealth prescribing flexibility for controlled substances

The agency said on Wednesday that it needs additional time to parse through the 38,000 public comments it received in response to a proposal to reintroduce stricter limits around telehealth prescribing.

Scroll to Top